Compare ALK & ADPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ALK | ADPT |
|---|---|---|
| Founded | 1932 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Air Freight/Delivery Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.9B | 4.5B |
| IPO Year | 2003 | 2019 |
| Metric | ALK | ADPT |
|---|---|---|
| Price | $39.64 | $29.40 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 16 | 9 |
| Target Price | ★ $56.56 | $28.31 |
| AVG Volume (30 Days) | ★ 2.7M | 2.3M |
| Earning Date | 10-22-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 63.89 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $10,426,000,000.00 | $276,976,000.00 |
| Revenue This Year | $10.86 | $5.94 |
| Revenue Next Year | $8.43 | $22.42 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 8.09 | ★ 54.77 |
| 52 Week Low | $33.03 | $12.00 |
| 52 Week High | $60.63 | $29.96 |
| Indicator | ALK | ADPT |
|---|---|---|
| Relative Strength Index (RSI) | 43.35 | 63.12 |
| Support Level | $39.38 | $15.47 |
| Resistance Level | $41.36 | $29.96 |
| Average True Range (ATR) | 1.45 | 1.36 |
| MACD | 0.08 | 0.02 |
| Stochastic Oscillator | 23.98 | 89.53 |
Alaska Air Group Inc operates two airlines, Alaska and Horizon, in three operating segments. The Alaska Airlines segment includes scheduled air transportation on Alaska's Boeing and Airbus jet aircraft for passengers and cargo throughout the U.S., and in parts of Mexico and Costa Rica. The Regional segment includes Horizon's and other third-party carriers' scheduled air transportation for passengers across a shorter distance network within the U.S. and Canada under capacity purchase agreements. The Hawaiian Airlines segment includes scheduled air transportation on Hawaiian's Boeing and Airbus aircraft for passengers and cargo. It earns revenues from Passenger tickets, including ticket breakage and net of taxes and fees, Passenger ancillary, and Mileage Plan passenger revenue.
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.